CHF129.60 Novartis (NOVN.SW, SIX) intraday 26 Feb 2026: Meyka sees 18.35% upside
NOVN.SW stock trades at CHF129.60 intraday on the SIX exchange on 26 Feb 2026, with 3,670,447 shares traded and a high near CHF129.60. Volume is 1.25 times average, keeping Novartis among Switzerland’s most active names. Short-term momentum is strong, but valuation and near-term forecasts diverge, making active monitoring important.
NOVN.SW stock intraday snapshot
Novartis (NOVN.SW) is trading at CHF129.60 with a day low of CHF126.98 and a year high of CHF129.84. Market cap sits near CHF247.68 billion and the stock opened at CHF127.54. Reported EPS is 5.50 and the PE ratio is 23.60. Average daily volume is 3,213,749 shares; today’s volume is 3,670,447, giving a relative volume of 1.25.
NOVN.SW stock: recent news drivers
Recent company moves are active catalysts. Novartis announced a US radioligand therapy plant in Texas and real-world data supporting Pluvicto use, supporting long-term revenue mix changes. See Reuters coverage for background and corporate context: Reuters Novartis profile.
The group also agreed to sell its listed Indian unit stake and signed licensing deals for cardiovascular and peptide programs, sharpening both near-term cash flow and strategic focus. Nasdaq covered production investment news and trial updates that influence investor sentiment: Nasdaq report on US manufacturing expansion.
NOVN.SW stock fundamentals and valuation
Novartis shows solid margins and cash generation. Key metrics: revenue per share 29.41, free cash flow per share 8.76, return on equity 32.80%, and dividend per share 4.53 (yield about 2.70%). Price-to-book is 6.97 and price-to-sales is 5.70, both above typical peer medians. Compared with the healthcare sector PE average of 35.67, Novartis trades at a lower PE of 23.60, suggesting relative valuation support.
NOVN.SW stock technicals and trading signals
Momentum indicators are stretched. RSI reads 80.75 (overbought) and MACD shows a small positive histogram. ADX at 33.11 signals a strong trend. Price sits above the 50-day average (CHF115.25) and 200-day average (CHF103.33). Bollinger upper band is CHF132.57, implying limited near-term upside without a pullback. Traders should note an ATR of 2.08 for position sizing.
Meyka grade and model forecasts for NOVN.SW stock
Meyka AI rates NOVN.SW with a score of 78.14 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF124.35, quarterly CHF133.50, yearly CHF114.47, three-year CHF134.05, and five-year CHF153.37. Versus the current CHF129.60, the model implies a near-term upside to the quarterly forecast of +3.01% and a five-year upside of +18.35%. Forecasts are model-based projections and not guarantees.
NOVN.SW stock outlook, analyst views and risks
Independent ratings show mixed signals. A recent company rating dated 2026-02-24 assigns Novartis a B+ with a Neutral recommendation; DCF signals Buy while leverage metrics warrant caution. Key risks include patent expiries, regulatory reviews, and integration costs from US capacity build-outs. Balance-sheet metrics remain solid with interest coverage near 15.13 and net debt to EBITDA around 1.12, but high price-to-book invites valuation sensitivity to earnings shocks.
Final Thoughts
Novartis (NOVN.SW) sits at CHF129.60 on the SIX exchange with active intraday volume and strong momentum. Fundamentals show healthy cash flow per share (8.76) and high ROE (32.80%), while valuation metrics such as P/B 6.97 and P/S 5.70 look rich versus some peers. Technicals warn of short-term overbought conditions (RSI 80.75). Meyka AI rates NOVN.SW 78.14/100 (B+, BUY) and offers a range of model outputs. Meyka AI’s forecast model projects a quarterly target of CHF133.50 (+3.01%) and a five-year target of CHF153.37 (+18.35%) versus today’s price. Investors should weigh the model upside against execution and regulatory risks. For traders, short-term setups favour profit-taking on sharp rallies. For longer-term investors, the mix of strong cash flow, pipeline catalysts, and a constructive Meyka grade supports a watch-to-buy stance, provided exposure is size-managed and re-evaluated after upcoming earnings and trial readouts. For the live quote and additional data, see Novartis on Meyka: Novartis NOVN.SW on Meyka.
FAQs
What is the current price and volume for NOVN.SW stock?
NOVN.SW stock trades at CHF129.60 intraday with volume at 3,670,447 shares. Day range is CHF126.98–CHF129.60, and relative volume is about 1.25 versus its 50-day average.
How does Meyka rate NOVN.SW stock and why?
Meyka AI rates NOVN.SW 78.14/100 (B+, BUY). The grade balances benchmark and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Grades are informational and not investment advice.
What near-term price target does Meyka give for NOVN.SW stock?
Meyka’s model lists a quarterly target of CHF133.50, implying a +3.01% move from CHF129.60. Models can diverge; treat targets as scenario guides, not guarantees.
What are the main risks for NOVN.SW stock investors?
Primary risks include patent expiries, regulatory setbacks, and execution costs for new manufacturing capacity. Valuation sensitivity is high given elevated price-to-book and price-to-sales ratios.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.